- Home
- CCEL vs SCYX Comparison
CCEL vs SCYX Comparison
Compare CCEL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCEL
- SCYX
- Stock Information
- Founded
- CCEL 1989
- SCYX 1999
- Country
- CCEL United States
- SCYX United States
- Employees
- CCEL N/A
- SCYX N/A
- Industry
- CCEL Managed Health Care
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- CCEL Health Care
- SCYX Health Care
- Exchange
- CCEL Nasdaq
- SCYX Nasdaq
- Market Cap
- CCEL 50.0M
- SCYX 50.3M
- IPO Year
- CCEL 1997
- SCYX 2014
- Fundamental
- Price
- CCEL $7.40
- SCYX $1.12
- Analyst Decision
- CCEL
- SCYX Buy
- Analyst Count
- CCEL 0
- SCYX 1
- Target Price
- CCEL N/A
- SCYX N/A
- AVG Volume (30 Days)
- CCEL 13.7K
- SCYX 316.4K
- Earning Date
- CCEL 02-26-2025
- SCYX 11-06-2024
- Dividend Yield
- CCEL 3.38%
- SCYX N/A
- EPS Growth
- CCEL N/A
- SCYX N/A
- EPS
- CCEL N/A
- SCYX N/A
- Revenue
- CCEL $31,838,476.00
- SCYX $8,566,000.00
- Revenue This Year
- CCEL $3.97
- SCYX N/A
- Revenue Next Year
- CCEL $0.91
- SCYX $365.06
- P/E Ratio
- CCEL N/A
- SCYX N/A
- Revenue Growth
- CCEL 1.95
- SCYX N/A
- 52 Week Low
- CCEL $4.47
- SCYX $0.90
- 52 Week High
- CCEL $9.50
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- CCEL 46.30
- SCYX 44.06
- Support Level
- CCEL $6.74
- SCYX $1.12
- Resistance Level
- CCEL $7.50
- SCYX $1.49
- Average True Range (ATR)
- CCEL 0.42
- SCYX 0.10
- MACD
- CCEL -0.02
- SCYX -0.00
- Stochastic Oscillator
- CCEL 56.42
- SCYX 27.31
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from cellular processing and cryogenic storage and it derives revenue from processing and testing fees and storage segment.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.